Pharma Equity Group A/S (CPH: PEG)

Market Cap	214.82M
Revenue (ttm)	n/a
Net Income (ttm)	-30.81M
Shares Out	1.02B
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,264,777
Open	0.232
Previous Close	0.236
Day's Range	0.203 - 0.236
52-Week Range	0.180 - 0.560
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 15, 2024

About Pharma Equity Group

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Denmark
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: PEG